Osimertinib (osimertinib) can take up to several years to become resistant to drug resistance. How to deal with drug resistance?

Osimertinib, trade name Tagrisso, is a third-generation targeted drug for non-small cell lung cancer (NSCLC), especially patients with EGFR mutation-positive patients. By specifically inhibiting the activity of EGFR mutant protein, it effectively prevents the growth and spread of tumor cells, bringing new treatment hope to many patients who are insensitive or resistant to traditional chemotherapy drugs. The emergence of osimertinib has undoubtedly injected new vitality into the field of lung cancer treatment and significantly improved the quality of life and survival of patients.

However, any drug has its limitations, and osimertinib is no exception. Although it shows excellent results in initial treatment, some patients may develop resistance over time. The development of drug resistance is a complex process that may be related to a variety of factors, such as genetic mutations, changes in drug metabolism, etc. Therefore, the maximum effective time of osimertinib varies from person to person and cannot be generalized.

When resistance to osimertinib occurs, patients and doctors need to face new challenges together and find new treatment strategies. First, genetic testing is a crucial step. Through genetic testing, the specific reasons for drug resistance can be clarified, such as whether there are new genetic mutations. This helps doctors develop personalized treatment plans for patients.

Treatment options will vary depending on the cause of drug resistance. If resistance is due to new genetic mutations, doctors may consider using other targeted drugs or a combination of multiple targeted drugs to overcome the resistance. For example, some new targeted drugs may target specific genetic mutations and thereby restore the inhibitory effect on tumor cells. In addition, chemotherapy and immunotherapy are also options for patients with drug resistance. Chemotherapy drugs kill cancer cells by inhibiting cell division, while immunotherapy modulates the immune system to attack cancer cells. During the treatment process, patients and doctors need to communicate closely, jointly monitor changes in the condition, and adjust the treatment plan according to the patient's specific situation.

In short, osimertinib, as an important targeted drug, plays an important role in the treatment of lung cancer. However, the emergence of drug resistance is inevitable. When resistance to osimertinib occurs, patients and doctors need to face new challenges together and overcome resistance through genetic testing and the development of personalized treatment plans. Only in this way can patients be ensured to obtain the best treatment effect and quality of life.